Literature DB >> 6329923

Glucagonoma syndrome demonstrating giant duodenal villi.

F M Stevens, R W Flanagan, D O'Gorman, K D Buchanan.   

Abstract

A 39 year old man developed an itchy bullous rash in the perineum and on the extremities. Six years later, after giant intestinal villi had been noted at endoscopy, a diagnosis of the glucagonoma syndrome was made. Investigation revealed a large tumour of the pancreatic body and tail. The molecular species of glucagon secreted by the tumour were characterised using the combined purification procedures of immunoaffinity chromatography followed by gel filtration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329923      PMCID: PMC1432604          DOI: 10.1136/gut.25.7.784

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Comparison of non-biospecific effects in immunoaffinity chromatography using cyanogen bromide and bifunctional oxirane as immobilising agents.

Authors:  R F Murphy; J M Conlon; A Imam; G J Kelly
Journal:  J Chromatogr       Date:  1977-05-21

2.  Glucagonoma syndrome in a young man.

Authors:  N G Soler; G D Oates; J M Malins
Journal:  Proc R Soc Med       Date:  1976-06

3.  Cure of insulin-dependent diabetes mellitus by removal of a glucagonoma.

Authors:  S L Lightman; S R Bloom
Journal:  Br Med J       Date:  1974-03-02

4.  A glucagonoma syndrome.

Authors:  C N Mallinson; S R Bloom; A P Warin; P R Salmon; B Cox
Journal:  Lancet       Date:  1974-07-06       Impact factor: 79.321

5.  Enzymic iodination of the histidyl residue of secretin: a radioimmunoassay of the hormone.

Authors:  K N Holohan; R F Murphy; R W Flanagan; K D Buchanan; D T Elmore
Journal:  Biochim Biophys Acta       Date:  1973-09-21

6.  Antibodies to unconjugated synthetic and natural secretins.

Authors:  K D Buchanan; J D Teale; G Harper
Journal:  Horm Metab Res       Date:  1972-11       Impact factor: 2.936

7.  An enteroglucagon tumour.

Authors:  S R Bloom
Journal:  Gut       Date:  1972-07       Impact factor: 23.059

8.  Pentagastrin-induced stimulation of protein synthesis in the gastrointestinal tract.

Authors:  L R Johnson; D Aures; L Yuen
Journal:  Am J Physiol       Date:  1969-07

Review 9.  Symposium on pathology of the gastrointestinal tract-Part II. Small intestinal biopsy.

Authors:  D R Perera; W M Weinstein; C E Rubin
Journal:  Hum Pathol       Date:  1975-03       Impact factor: 3.466

10.  Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function.

Authors:  M H Gleeson; S R Bloom; J M Polak; K Henry; R H Dowling
Journal:  Gut       Date:  1971-10       Impact factor: 23.059

View more
  15 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 2.  Enhancing bowel adaptation in short bowel syndrome.

Authors:  Palle Bekker Jeppesen; Per Brobech Mortensen
Journal:  Curr Gastroenterol Rep       Date:  2002-08

Review 3.  The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective.

Authors:  Palle Bekker Jeppesen
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

4.  Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats.

Authors:  M A Ghatei; R A Goodlad; S Taheri; N Mandir; A E Brynes; M Jordinson; S R Bloom
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

5.  Modulation of specific intestinal epithelial progenitors by enteric neurons.

Authors:  M Bjerknes; H Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

6.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

Authors:  D J Drucker; P Erlich; S L Asa; P L Brubaker
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 7.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

8.  Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation.

Authors:  Belinda van't Land; Noortje M A van Beek; Jeroen J M van den Berg; Laura M'Rabet
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

Review 9.  Novel therapies for the management of short bowel syndrome in children.

Authors:  Marshall Z Schwartz
Journal:  Pediatr Surg Int       Date:  2013-10       Impact factor: 1.827

10.  Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Authors:  P B Jeppesen; P Lund; I B Gottschalck; H B Nielsen; J J Holst; J Mortensen; S S Poulsen; B Quistorff; P B Mortensen
Journal:  Gastroenterol Res Pract       Date:  2009-08-20       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.